Critical illness products are continually evolving worldwide. With this in mind, Greg Becker checks out some interesting developments in Hong Kong.
Companies continuously try to differentiate their offerings, trying to make their proposition better in some way. Many would argue this has just made the customer’s job of comparing products even harder, and discerning whether or not a newly added disease is a benefit of value is something that is hard to ascertain. RGA’s Critical Illness (CI) Cards put diseases in context, with the likely incidence rates and claim experience being reported. But this is only one of many dimensions on which policies can be compared. Some companies have differentiated themselves based on distribution ch...
To continue reading this article...
Join Professional Adviser
- Unlimited access to real-time news, industry insights and market intelligence.
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters.
- Make smart business decisions with the latest developments in regulation, investing retirement and protection.
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes.